Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Caladrius Biosciences, Inc. (NASDAQ: CLBS).

Full DD Report for CLBS

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLBS)

Caladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET
BASKING RIDGE, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimm...
Source: GlobeNewswire
Date: November, 02 2018 08:00
Caladrius Biosciences to Participate in Upcoming October Conferences
Company Receives “Buzz of BIO” Award at the 2018 BIO Investor Forum BASKING RIDGE, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company ...
Source: GlobeNewswire
Date: September, 27 2018 08:00
Caladrius Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
BASKING RIDGE, N.J., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indic...
Source: GlobeNewswire
Date: August, 30 2018 08:00
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2018 Results - Earnings Call Transcript
Caladrius Biosciences, Inc. (CLBS) Q2 2018 Earnings Conference Call August 09, 2018 04:30 PM ET Executives John Menditto - Executive Director, IR & Corporate Communications David Mazzo - President and CEO Joseph Talamo - SVP and CFO Analysts Keay Nakae - Chardan Jul...
Source: SeekingAlpha
Date: August, 09 2018 20:27
Caladrius Biosciences beats by $0.22
Caladrius Biosciences (NASDAQ: CLBS ): Q2 EPS of -$0.42 beats by $0.22 . Cash, cash equivalents and marketable securities of $50.32M Press Release More news on: Caladrius Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: August, 09 2018 16:08
Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results
BASKING RIDGE, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indic...
Source: GlobeNewswire
Date: August, 09 2018 16:05
Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET
BASKING RIDGE, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmu...
Source: GlobeNewswire
Date: August, 02 2018 08:00
Caladrius Biosciences Strikes Gold With Acquisition Of Late-Stage Refractory Angina Therapy From Shire
Those that follow my articles know that I tend to focus mainly on undervalued microcap or smallcap biotech companies. A lot of my recommendations result in short-term gains as they usually surround clinical updates or upcoming catalysts. However, many take longer to play out and require some p...
Source: SeekingAlpha
Date: June, 25 2018 20:07
Midday Gainers / Losers (06/21/2018)
Gainers: XBIO +151% . ABIL +79% . ASCMA +48% . SBOT +38% . HRTX +33% . RYTM +23% . BNED +20% . BOXL +17% . BFR +16% . AVLR +14% . More news on: Xenetic Biosciences, Inc., Ability Inc., Ascent Capital Group, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: June, 21 2018 12:41
Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges
Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin...
Source: SeekingAlpha
Date: June, 21 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-124.834.714.944.680126,013
2018-12-114.974.855.01594.813,601
2018-12-104.804.724.914.6848,143
2018-12-074.734.744.8524.704,643
2018-12-064.774.734.934.7015,644

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-127,48411,63964.3011Short
2018-12-1176487587.3143Short
2018-12-106,78117,35239.0791Short
2018-12-0710189711.2598Cover
2018-12-062,45410,81922.6823Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLBS.


About Caladrius Biosciences, Inc. (NASDAQ: CLBS)

Logo for Caladrius Biosciences, Inc. (NASDAQ: CLBS)

Not available

 

Contact Information

 

 

Current Management

  • Robin Smith / CEO
    • Robin L. Smith, M.D. joined our Board of Directors as its Chairman on August , . She received her M.D. from Yale University and M.B.A. from the Wharton School of Business. During her tenure as CEO of the Caladrius Biosciences, Inc. formerly NeoStem Inc. NASDAQ: CLBS , which she led from to , she pioneered the company s innovative business model, combining proprietary cell therapy development with a contract development and manufacturing organization. Dr. Smith raised over million, completing six acquisitions and one divestiture for which the company won multiple recognition awards. Dr. Smith founded The Stem for Life Foundation SFLF , an educational organization devoted to fostering global awareness of regenerative medicine. In , Dr. Smith forged a partnership with The Vatican to collaboratively create highprofile initiatives to reduce global human suffering. Dr. Smith has served as Chairman of the Board and President of the Stem for life Foundation since its inception and is expanding its mission further under the Cura brand. Dr. Smith also serves on the Boards of Directors of Rockwell Medical NASDAQ: RMTI , Signal Genetics NASDAQ: SGNL , and Bioxcel Corporation. She serves as Vice President and Board member of the STOQ Foundation in Rome and the Board of Overseers at the NYU Langone Medical Center.

Current Share Structure

  • Market Cap: $38,306,139 - 05/15/2018
  • Issue and Outstanding: 9,552,653 - 03/22/2018

 


Recent Filings from (NASDAQ: CLBS)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 24 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 24 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 08 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (NASDAQ: CLBS)

Daily Technical Chart for (NASDAQ: CLBS)


Stay tuned for daily updates and more on (NASDAQ: CLBS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CLBS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLBS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CLBS and does not buy, sell, or trade any shares of CLBS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/